Aggregated presentation by day and by market Purchases of own shares from July 29th to August 2nd, 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the...
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article...
Aggregated presentation by day and by market Purchases of own shares from July 22th to 26th, 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the...
While it may well be the dog days of summer, European drug regulators are showing no signs of slowing down in their review of new medicines and proposed label expansions.nnIn a busy meeting this week, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) signed off on seven new medicines, six biosimilars and 11 label expansions for existing drugs. In addition, Accord's generic to Pfizer's tyrosine kinase inhibitor Inlyta gained a CHMP thumbs-up, according to CHMP's meeting summary.
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases CHMP positive...
Ipsen secures ex-U.S. regulatory and commercial rights to tovorafenib for most common childhood brain tumor, pediatric low-grade glioma (pLGG), and any future indicationsOJEMDA™ (tovorafenib) is...
PARIS, FRANCE, 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024. Business...
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) Attachment 2024 Ipsen Half-Year Financial Report ...
Just three months after scoring an accelerated FDA approval for Ojemda, Day One Biopharmaceuticals is teaming up with another fellow oncology specialist to grow the medicine's global reach.
Aggregated presentation by day and by market Purchases of own shares from July 15th to 19th, 2024 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code...